Figure 7 | Scientific Reports

Figure 7

From: Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis

Figure 7

Novel therapeutic decision tree to overcome chemoresistant SCLC based on HER2 expression.

After HER2 is detected by IHC at the time of diagnosis, patients are divided into two groups according to the 1st line chemotherapy. Trastuzumab- or bevacizumab-based 2nd line chemotherapy is ideal for patients who have acquired resistance to etoposide-based or irinotecan-based 1st line chemotherapy, respectively. Upregulation of both HER2 and ICAM-1 in etoposide-resistant SCLC cells facilitates trastuzumab-mediated ADCC. Abundant VEGF produced from irinotecan-resistant SCLC cells is the main target of bevacizumab.

Back to article page